GBA's "2021 Stock Phantasma"

Heavy Rain.

I have Seasonal Affliction Disorder / there has been no sun in like 3 weeks. My tomatoes they no grow. Every day pouring rain. I left a tin bucket out last night to see how much 6 inches!
That's ontop of a recent 8. Get this- my wife, she left the car windows down! Back to ground zero with the mold and wetness.. did I say a thing? Nope. Did I make this some big grand awaking about her life in general.... Nope....
 
stonedinvestor said:
Heavy Rain.

I have Seasonal Affliction Disorder / there has been no sun in like 3 weeks. My tomatoes they no grow. Every day pouring rain. I left a tin bucket out last night to see how much 6 inches!
That's ontop of a recent 8. Get this- my wife, she left the car windows down! Back to ground zero with the mold and wetness.. did I say a thing? Nope. Did I make this some big grand awaking about her life in general.... Nope....
More...
There goes the stream bank. Up next... Stoney's foundation.
 
janes said:
this morning i'm thinking about 5G because of my new stock holding Nokia NOK. It seems that Nokia has had a series of CEO's that have bet on the wrong technology which has screwed the next CEO who attempts to recover by finding a new wrong technology to bet on. Since September, Nokia has a new CEO with a new turnaround plan (GBA thread doesn't really mention Nokia until the new CEO came on and since then Stoney you've posted little things that they've started to do, like a google cloud thing etc). What I've read says that new CEO is making right decisions but Nokia is really behind on 5G and do they have the money to invest in order to recover ground.

There appears to be an opening for another 5G leader next to GBA favorite Ericsson ERIC because of bans on Huawei.

I'm thinking maybe enough WSB people keep their holdings in Nokia and it just putters along at elevated stock price. But what if they all sell and stock price drops to $4. Might be a nice opportunity?? Seems average price target is $4.37. Before WSB arrived, Nokia had a +15% trading day on 1/25 to rise to $4.85 based on a rating change. Nokia earning day 2/4/2021.
More...
you know, this research i did into nokia NOK back in january ended up holding up pretty well, though it was a bit of a stab in the dark at the time and i didn't end up keeping the stock. anything under $4 turned out to be a good deal, as stock has risen steadily and they seem to be getting a foothold into 5G
 
oh boy this has been quite a ride. ackman pulling PSTH out of universal music deal, is going to do his 10% stake with his investment fund instead.

https://www.businessinsider.com/bil...re-psth-spac-universal-music-stake-sec-2021-7

from business insider:
"The SPAC's board unanimously decided on Sunday to ditch the Universal deal after speaking to the SEC and realizing the agency would probably nix it. PSTH's directors will now focus on completing a conventional SPAC deal, and have 18 months to close one unless shareholders vote for an extension.

Ackman was caught off guard by the backlash from some PSTH shareholders to the complexity and structure of the original deal, he noted in his letter. The investor also underestimated its potential impact on investors who can't hold foreign securities, margin their shares, or own call options on PSTH stock, he added."
 
Good move by Ack... I hated that deal from the jump.

RLFTF- What is that? It's a 19 cent stock. I know.. but they are in partnership with an $8 stk named Nrx Pharm and they have an interesting drug...

  • NRx Pharmaceuticals(NASDAQ:NRXP), up 12% premarket presents evidence that Zyesami (aviptadil) helps prevent "Cytokine Storm" in patients with COVID-19.
  • In Phase 2b/3 trial, patients treated with placebo experienced a statistically significant elevation in interleukin 6 (IL-6) cytokine levels, whereas those treated with Zyesami had a minimal increase in IL-6.
  • Change in cytokine level was a prespecified endpoint of the study.
  • The anti-cytokine effect of Zyesami was additionally associated with a significant decrease in 60-day mortality.
  • The effect was noted across a diverse set of patients, with different levels of COVID-19 severity and treated in both tertiary care and community hospitals.
  • NRx has submitted these findings to the FDA as a supplement to its pending application for Emergency Use Authorization, and is submitting a biomarker letter of intent to the FDA as part of its biomarker program.
  • Zyesami (aviptadil) is being developed in partnership with Relief Therapeutics(OTCQB:RLFTF).<-------------


 
Aehr Test receives $10.8M order for silicon carbide test burn-in customer 07:33 AEHR Aehr Test Systems announced it has received a $10.8M single purchase order from its lead silicon carbide test and burn-in customer for multiple FOX-XP systems and full sets of WaferPak Contactors to meet their increased production capacity needs. This customer is a leading Fortune 500 supplier of semiconductor devices with a significant customer base in the automotive semiconductor market. These FOX systems and WaferPaks are expected to ship within the next six months. Gayn Erickson, President and CEO of Aehr Test Systems, commented, "These follow-on orders for additional FOX-XP systems and WaferPaks are the result of our working closely with this lead customer to achieve their test requirements and validation of our FOX-P platform and WaferPak full wafer contactors as their production qualified solution. This customer continues to forecast orders for multiple additional FOX systems and WaferPak Contactors this fiscal year and a significant number of systems and WaferPaks over the next several years due to electric vehicle semiconductor test and burn-in demand."
 
Global Payments designated as a bullish Fresh Pick at Baird 06:44 GPN Baird analyst David Koning raised the firm's price target on Global Payments to $252 from $250 and keeps an Outperform rating on the shares. The analyst designated the shares as a Fresh Pick and also raised his estimates. The stock has underperformed year-to-date yet he likes the strong Q2 beat and raise potential, likes that it is a later cycle play, and its steady above market earnings growth potential for many years to come.
 
Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief's lead drug candidate, RLF-100TM(aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease. In addition, Relief's acquisition of APR Applied Pharma Research brings a diverse pipeline of marketed and development-stage programs.
 
You must log in or register to reply here.
Back
Top